NDA 050207 · Carnegie
Eryped
Erythromycin Ethylsuccinate · Oral
Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1965
Apr 2, 1965
Approved uses
1
Original approval plus efficacy supplements
Registered trials
897
218 Phase 3, 47 recruiting
FAERS reports
609
361 serious, 35 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 16, 2023.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ery-Ped and other antibacterial drugs, Ery-Ped should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ery-Ped is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during...
Mechanism: Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated in vitro between erythromycin and clindamycin, lincomycin, and chloramphenicol.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 2, 1965 Original approval
3 products under this application
- ERYPED · ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML · GRANULE, ORAL · Prescription · TE AB
- E.E.S. · ERYTHROMYCIN ETHYLSUCCINATE EQ 200MG BASE/5ML · GRANULE, ORAL · Prescription · TE AB
- ERYPED · ERYTHROMYCIN ETHYLSUCCINATE EQ 400MG BASE/5ML · GRANULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Erythromycin Ethylsuccinate" as an intervention, any sponsor and status, largest first.
- Azithromycin for Child Survival in Niger IIPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06358872 · 3,300,000 participants (planned) · Start Apr 29, 2024 · Primary completion Apr 29, 2028
Drug: Azithromycin for Oral Suspension · For: Mortality; Antimicrobial Resistance
Sites: Niamey, Niger
- Azithromycin for Child Survival in Niger: Mortality and Resistance TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04224987 · 864,493 participants · Start Nov 24, 2020 · Primary completion Jul 31, 2024
Drug: Azithromycin · For: Mortality; Resistance Bacterial; Child, Only
Sites: Niamey, Niger
FHI 360Academic, hospital or other
NCT05016895 · 767,535 participants · Start Aug 27, 2021 · Primary completion Jun 30, 2024
Drug: Single-dose azithromycin · For: Child Mortality
Sites: Abidjan, Côte d’Ivoire
- Infant Mortality Reduction by the Mass Administration of AzithromycinPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT04716712 · 694,400 participants (planned) · Start Oct 4, 2021 · Primary completion Jan 30, 2025
Drug: Azithromycin; Placebo · For: Child Mortality
Sites: San Francisco, California; Nouna, Burkina Faso; Ouagadougou, Burkina Faso
- Kebele Elimination of Trachoma for Ocular HealthPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT03335072 · 320,000 participants (planned) · Start Feb 7, 2022 · Primary completion Mar 1, 2027
Drug: Azithromycin · For: Trachoma
Sites: San Francisco, California; Bahir Dar, Ethiopia
- Mortality Reduction After Oral Azithromycin: Mortality StudyPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02047981 · 190,238 participants · Start Dec 2014 · Primary completion Sep 2018
Drug: Azithromycin; Placebo · For: Childhood Mortality
Sites: San Francisco, California; Baltimore, Maryland; Blantyre, Malawi · 6 sites in all
- Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)Pivotal-lookingTerminated
University of California, San FranciscoAcademic, hospital or other
NCT05288023 · 169,707 participants · Start Dec 1, 2022 · Primary completion Jan 15, 2024
Drug: Azithromycin for Oral Suspension · For: Resistance Bacterial; Morality; Child Health and 1 more
Sites: San Francisco, California
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in MaliPivotal-lookingCompleted
Tampere UniversityAcademic, hospital or other
NCT04424511 · 149,201 participants · Start Oct 15, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Azithromycin · For: Mortality
Sites: Bamako, Mali
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity72
- vomiting45
- nausea41
- diarrhoea36
- off label use34
- rash24
- dyspnoea23
- hypersensitivity22
- product use in unapproved indication22
- abdominal pain21
- pruritus21
- urticaria17
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 11 |
| 2006 | 8 |
| 2007 | 5 |
| 2008 | 15 |
| 2009 | 13 |
| 2010 | 30 |
| 2011 | 26 |
| 2012 | 17 |
| 2013 | 35 |
| 2014 | 21 |
| 2015 | 17 |
| 2016 | 45 |
| 2017 | 37 |
| 2018 | 46 |
| 2019 | 53 |
| 2020 | 32 |
| 2021 | 30 |
| 2022 | 13 |
| 2023 | 31 |
| 2024 | 45 |
| 2025 | 45 |
| 2026 | 21 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis.
Hoppe JE, Halm U, Hagedorn HJ, et al. · Infection 1989 · Clinical Trial, Comparative Study
- Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses.
Yakatan GJ, Rasmussen CE, Feis PJ, et al. · J Clin Pharmacol 1985 · Clinical Trial, Comparative Study
- Relative bioavailability of enteric coated pellets, stearate and ethylsuccinate formulations of erythromycin.
Tjandramaga TB, Van Hecken A, Mullie A, et al. · Pharmacology 1984 · Clinical Trial, Comparative Study
- Roxithromycin, a new macrolide antibiotic, in the treatment of infections in the lower respiratory tract: an overview.
Gentry LO · J Antimicrob Chemother 1987 · Clinical Trial, Randomized Controlled Trial
- The effect of erythromycin on the nasopharyngeal pathogens in children with secretory otitis media.
Sundberg L, Cederberg A, Edén T, et al. · Acta Otolaryngol 1984 · Clinical Trial, Randomized Controlled Trial
- Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori.
McNulty CA · Rev Infect Dis 1990 · Clinical Trial, Randomized Controlled Trial
Sponsor: Carnegie · Also marketed as E.E.S.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.